5.29
-0.15 (-2.76%)
| Previous Close | 5.44 |
| Open | 5.51 |
| Volume | 596,609 |
| Avg. Volume (3M) | 404,181 |
| Market Cap | 137,924,048 |
| Price / Sales | 2.96 |
| Price / Book | 2.47 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2025 - 1 Aug 2025 |
| Profit Margin | -116.91% |
| Operating Margin (TTM) | -66.97% |
| Diluted EPS (TTM) | -2.65 |
| Quarterly Revenue Growth (YOY) | 35.70% |
| Total Debt/Equity (MRQ) | 70.98% |
| Current Ratio (MRQ) | 12.06 |
| Operating Cash Flow (TTM) | -39.14 M |
| Levered Free Cash Flow (TTM) | -20.93 M |
| Return on Assets (TTM) | -29.91% |
| Return on Equity (TTM) | -81.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | CVRx, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.90% |
| % Held by Institutions | 70.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Canaccord Genuity, 240.27%) | Buy |
| Median | 13.00 (145.75%) | |
| Low | 7.00 (JP Morgan, 32.33%) | Sell |
| Average | 12.75 (141.02%) | |
| Total | 3 Buy, 1 Sell | |
| Avg. Price @ Call | 5.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 09 May 2025 | 7.00 (32.33%) | Sell | 4.77 |
| Piper Sandler | 09 May 2025 | 12.00 (126.84%) | Buy | 4.77 |
| Canaccord Genuity | 08 Apr 2025 | 18.00 (240.26%) | Buy | 6.20 |
| Lake Street | 08 Apr 2025 | 14.00 (164.65%) | Buy | 6.20 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 May 2025 | Announcement | CVRx Reports First Quarter 2025 Financial and Operating Results |
| 24 Apr 2025 | Announcement | CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025 |
| 07 Apr 2025 | Announcement | CVRx Reports Preliminary First Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |